A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus Sorafenib. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or Sorafenib, with 2:1 random ratio. Every 21 days is a treatment cycle.
Advanced Hepatocellular Carcinoma (HCC)
DRUG: AK105 Injection|DRUG: Anlotinib Hydrochloride Capsules|DRUG: Sorafenib Tosylate Tablets
Overall survival (OS), OS defined as the time from the first dose to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., Up to 96 weeks
Progression-free survival (PFS), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., Up to 96 weeks|Overall response rate（ORR）, Percentage of subjects achieving complete response (CR) and partial response (PR)., Up to 96 weeks|Disease control rate（DCR）, Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD)., Up to 96 weeks|Duration of Response (DOR), DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment., Up to 96 weeks
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus Sorafenib. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or Sorafenib, with 2:1 random ratio. Every 21 days is a treatment cycle.